Unknown

Dataset Information

0

Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.


ABSTRACT: Stage IIIA non-small cell lung cancer (NSCLC) is heterogeneous in tumor burden, and its treatment is variable. Whole-body metabolic tumor volume (MTVWB) has been shown to be an independent prognostic index for overall survival (OS). However, the potential of MTVWB to risk-stratify stage IIIA NSCLC has previously been unknown. If we can identify subgroups within the stage exhibiting significant OS differences using MTVWB, MTVWB may lead to adjustments in patients' risk profile evaluations and may, therefore, influence clinical decision making regarding treatment. We estimated the risk-stratifying capacity of MTVWB in stage IIIA by comparing OS of stratified stage IIIA with stage IIB and IIIB NSCLC.We performed a retrospective review of 330 patients with clinical stage IIB, IIIA, and IIIB NSCLC diagnosed between 2004 and 2014. The patients' clinical TNM stage, initial MTVWB, and long-term survival data were collected. Patients with TNM stage IIIA disease were stratified by MTVWB. The optimal MTVWB cutoff value for stage IIIA patients was calculated using sequential log-rank tests. Univariate and multivariate cox regression analyses and Kaplan-Meier OS analysis with log-rank tests were performed.The optimal MTVWB cut-point was 29.2 mL for the risk-stratification of stage IIIA. We identified statistically significant differences in OS between stage IIB and IIIA patients (p?

SUBMITTER: Finkle JH 

PROVIDER: S-EPMC6048959 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Finkle Joshua H JH   Jo Stephanie Y SY   Ferguson Mark K MK   Liu Hai-Yan HY   Zhang Chenpeng C   Zhu Xuee X   Yuan Cindy C   Pu Yonglin Y  

European journal of nuclear medicine and molecular imaging 20170307 8


<h4>Objectives</h4>Stage IIIA non-small cell lung cancer (NSCLC) is heterogeneous in tumor burden, and its treatment is variable. Whole-body metabolic tumor volume (MTV<sub>WB</sub>) has been shown to be an independent prognostic index for overall survival (OS). However, the potential of MTV<sub>WB</sub> to risk-stratify stage IIIA NSCLC has previously been unknown. If we can identify subgroups within the stage exhibiting significant OS differences using MTV<sub>WB</sub>, MTV<sub>WB</sub> may le  ...[more]

Similar Datasets

| S-EPMC8612197 | biostudies-literature
| S-EPMC4767117 | biostudies-literature
| S-EPMC5758229 | biostudies-literature
| S-EPMC7685366 | biostudies-literature
| S-EPMC5662551 | biostudies-literature
| S-EPMC7354116 | biostudies-literature
| S-EPMC8182703 | biostudies-literature
| S-EPMC6463892 | biostudies-literature
| S-EPMC6629568 | biostudies-literature
| S-EPMC3360908 | biostudies-literature